CRH plc isn’t the only FTSE 100 growth share I’d buy today

The FTSE 100 (INDEXFTSE: UKX) is packed with growth stocks that can make investors a fortune. Here are two such shares, including one making lots of headlines right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The long-running international expansion plan over at CRH (LSE: CRH) convinces me that it should remain an impressive growth generator for many years to come.

CRH — a multinational giant in the provision of building materials — has seen earnings swell at a compound annual growth rate of 27.7% during the past five years, and Thursday’s bubbly trading statement convinces me that earnings can continue pounding higher.

The FTSE 100 firm sprang 3% today after announcing that revenues rose 2% in 2017 to €27.6bn, with like-for-like sales rising by the same percentage. As a result, pre-tax profit at CRH boomed 16% year-on-year to €2.01bn.

Celebrating the result, chief executive Albert Manifold commented: “2017 was a year of continued profit growth for CRH. We benefitted from increases in underlying demand in the Americas and positive momentum in Europe, and with focus on performance improvement and operational delivery, margins and returns were ahead of last year in our American and European Divisions.”

He added that the ongoing economic recovery should underpin further progress in 2018.

M&A mammoth

Now City analysts are expecting earnings expansion to cool in the more immediate future, a 5% rise forecast for 2018. However, this is expected to prove a temporary slowdown as a return to double-digit growth is predicted in 2019, by 13%.

CRH has tremendous scale which puts it in the box seat to exploit improving market conditions across many global markets. The company’s enthusiastic M&A drive is expanding its footprint in key geographies and sectors. It made 31 acquisitions and three investments last year for a combined €1.9bn, up from the 24 acquisitions and investments made in 2016.

And CRH still has the monster €3.5bn takeover of US cement mammoth Ash Grove to come later this year, of course, while it is still eyeing up acquisitions elsewhere to keep profits moving skywards.

A forward P/E ratio of 14.3 times does not reflect CRH’s bright earnings outlook, in my opinion. It’s a Footsie bargain worthy of serious attention.

Medical marvel

Smith & Nephew (LSE: SN) is another Footsie share I am tipping to deliver strong and sustained profits expansion.

The Square Mile is touting a 4% earnings improvement in 2018, and an extra 7% rise is predicted for 2019.

Now current projections make the artificial limb and joint builder a tad toppy on paper, Smith & Nephew carrying a forward P/E multiple of 18.2 times. This is a small price to pay for the company’s rising might in lucrative developing markets however.

Group revenues rose 5% in 2017 to £1.28bn, the firm advised this month, driven by a 12% sales improvement from its emerging economies. This was thanks in large part to improving conditions in the Asian engine room of China, where sales rose by double-digit percentages last year.

Smith & Nephew commented in the results report: “We are well positioned to continue to drive strong growth from the emerging markets over the medium term.” And this is hardly a surprise as rising population levels and improving economic might underpin increases in healthcare budgets, and the FTSE 100 stock’s conveyor belt of cutting-edge technologies continues to win plaudits.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »